Siltuximab

Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research[1][2][3].

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model[1]. Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model[4]. Animal Model: Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg; 3 times per week Result: Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells. Repressed PY-STAT3 levels in H1650 cells. Inhibited the growth of tumors with H322 and CAF cells. Inhibited the growth of tumors with H1650 and CAF cells. Animal Model: Female NOD-SCID mice with MCF-7 tumor[4] Dosage: 20 mg/kg Administration: Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks Result: Blocked MCF-7 engraftment, induced regressions in 90% of tumors.